The Memo: CoreMotion Making Pelvic Floor Function Measurable

Under the direction of Founder and CEO Hee-Ju Han, CoreMotion is developing technology designed to make pelvic floor assessment and rehabilitation more objective, measurable, and accessible. Founded by a physiotherapist who witnessed firsthand the challenges facing patients with pelvic floor dysfunction, the South Korea-based company is transforming traditionally subjective evaluations into quantifiable data. With its flagship platform, PeriK, CoreMotion aims to help clinicians better assess function, track rehabilitation progress, and communicate treatment plans while laying the foundation for what Han envisions as one of the first comprehensive pelvic floor function data platforms.

Origin Story

CoreMotion’s origins trace back to Han’s clinical work as a CAPP-Pelvic certified physiotherapist at a Korean university hospital, where she helped introduce pelvic floor physical therapy within the Department of Urology.

Working directly with patients suffering from urinary incontinence, pelvic organ prolapse, and other pelvic floor disorders, Han repeatedly encountered the same challenge. Many patients were not receiving appropriate care, often because access to specialized therapy was limited and clinicians lacked objective ways to assess and explain pelvic floor function.

“At the center of this problem, I saw the absence of a standardized measurement tool that could objectively explain pelvic floor function,” Han explained. “I believed that introducing a technology that could solve this problem would create a common language among clinicians.”

For Han, the goal was not simply to improve care for individual patients.

“As one therapist, I could help one patient at a time,” she said. “But by building this company and developing this technology, I believed I could help lower the barriers to care for many more people.”

That vision became the foundation for CoreMotion’s mission: helping make pelvic floor assessment and rehabilitation more accessible, measurable, and easier to communicate between clinicians and patients. 

The Current Landscape

Pelvic floor dysfunction remains one of healthcare’s most common yet under-addressed conditions. Pelvic floor dysfunction includes conditions such as urinary incontinence, pelvic organ prolapse, pelvic pain, and postpartum pelvic floor problems, all of which can deeply affect quality of life, daily activities, sexual health, social participation, and mental well-being.

According to Han, the challenge is not a lack of treatment options. Pelvic floor physical therapy, exercise programs, biofeedback, medications, and surgery are all available. The larger issue is helping patients access the right care and ensuring clinicians have objective tools to guide treatment.

Studies suggest roughly one in four women experiences at least one symptomatic pelvic floor disorder, while urinary incontinence alone affects more than 20% of adults globally, with women representing the majority of cases. As populations age and postpartum recovery needs continue to grow, the burden is expected to increase.

Yet assessment methods have changed little.

“The current standard method for assessing pelvic floor function is digital palpation,” Han said. “This method is clinically very useful, but it has limitations in objectivity and reproducibility because it depends heavily on the examiner’s tactile sense and clinical experience.”

Even many quantitative tools rely primarily on pressure measurements. CoreMotion believes that approach captures only part of the picture.

“We believe function should be understood as movement,” Han explained. “It should include the direction of movement, speed, displacement, control strategy, and overall movement quality.”

Inside the Innovation

To address these limitations, CoreMotion developed PeriK, a platform designed to quantify pelvic floor function using force-displacement-based multisensor technology. Rather than replacing existing clinical workflows, the company designed the system to integrate naturally into how clinicians already perform examinations.

“Our approach is not to change the existing clinical workflow,” Han said. “Instead, we designed our technology to objectively measure and digitize what clinicians are already doing in daily practice.”

The platform combines a sensor-based wearable glove and a cylindrical assessment device capable of measuring tissue resting tone, contraction characteristics, and movement quality.

The assessment process consists of three primary stages:

• Contact quality confirmation, ensuring stable and reliable measurements before data collection begins.
• Resting tone assessment, measuring the mechanical properties of pelvic floor tissue through direct perpendicular compression of targeted muscles.
• Movement quality assessment, using real-time 3D movement analysis to evaluate range of motion, movement velocity, direction, symmetry, timing, coordination, and movement strategies.

After the assessment is completed, PeriK automatically generates a comprehensive report summarizing tissue resting tone, side-to-side differences, movement quality, movement strategies, and key rehabilitation indicators. The information can help clinicians explain conditions more clearly, establish individualized treatment goals, monitor progress, and support clinical decision-making throughout rehabilitation. 

For Han, the true differentiator is not the hardware itself, but the data it generates.

“What truly sets us apart is that we are not simply building another medical device. Our core asset is the data,” she said.

“We are not creating a new examination. We are making what clinicians already do measurable, explainable, and scalable.”

Progress and Milestones

CoreMotion has completed development of its core technology and prototypes and is now advancing toward clinical validation and early commercialization. The company reports it has reached Technology Readiness Level (TRL) 5 and has established partnerships with national university hospitals in South Korea to support pilot studies and early validation efforts.

The company is also building momentum internationally. CoreMotion is exploring validation collaborations in North America, including discussions with pelvic floor biomechanics researcher and Endowed Chair in Women’s Health Research at the University of Ottawa, Dr. Linda McLean, while also engaging commercialization organizations such as MaRS Discovery District and YSpace.

Additional milestones include:

• Achievement of ISO 13485 certification.
• Preparation for Korean medical device GMP certification.
• Planned North American launches of PhysioWand, a pelvic floor self-management device, and DRUDA Belt, a wearable device for lumbopelvic rehabilitation.
• Preparation for a $1.5 million Seed financing round to support clinical validation, commercialization, platform development, and team expansion.

Looking ahead, Han sees three priorities: clinical validation and standardization, platform expansion, and improved accessibility.

“We do not want to become simply another medical device company,” she said. “Our vision is to build a data platform for pelvic health based on the information generated by PeriK.”

Ultimately, CoreMotion sees PeriK as the foundation for something much larger than a measurement device.

“Our goal is to make pelvic floor function measurable, understandable, and manageable,” Han said. “Our long-term vision is to build the leading pelvic floor function data platform and help establish a new standard for objective assessment and rehabilitation in pelvic health.”

Join Us at LSI Asia ‘26

Han has been selected to present at LSI Asia '26, June 30th–July 3rd, in front of hundreds of global medical technology companies. Join us in welcoming her to the event in Singapore, where she will share the latest updates on CoreMotion’s technology and development.